sunbet

sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Á¬Ã¦ËÑË÷
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Á¬Ã¦ËÑË÷
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
½ÇĤÐÂÉúѪ¹Ü¶¯ÎïÄ£×Ó
Ä¿½ñλÖãºÊ×Ò³ > ÈËÀ༲²¡¶¯ÎïÄ£×ÓĿ¼ > ÑۿƼ²²¡Ä£×Ó > ½ÇĤÐÂÉúѪ¹Ü¶¯ÎïÄ£×Ó

ǰÑÔ

½ÇĤÐÂÉúѪ¹Ü(ehoroidal neovascularization,CNV)³£µ¼Ö½ÇĤ͸Ã÷¶È½µµÍ £¬ÊÇÖÂäµÄÒ»¸öÖ÷ÒªÔµ¹ÊÔ­ÓÉ £¬Ò²ÊǽÇÄ¤ÒÆÖ²Êõºó±¬·¢ÇãÔþ·´Ó¦µÄ¸ßΣÒòËØ¡£ÁÙ´²ÉÏCNVÖÎÁÆÈÔÊÇ×ÊÖµÄÎÊÌâÖ®Ò»¡£CNV¶¯ÎïÄ£×ÓÊôÓÚÓÕ·¢ÐÔ¼²²¡¶¯ÎïÄ£×Ó £¬Í¨¹ýÎïÀíÒªÁ죨ÈÈÉÕÀÓÊõºÍ½ÇĤ·ìÏß·¨µÈ£©¡¢»¯Ñ§ÒªÁ죨¼îÐÔ»¯Ñ§Ò©ÎïÉÕÉ˵ȣ©¡¢ÉúÎïÒªÁ죨½ÇĤÄÒ´üÅжϷ¨£©ºÍÊÖÊõÒªÁ죨ÒìÖÖ½ÇÄ¤ÒÆÖ²¡¢½ÇĤ»ùÖÊÄÚ×¢ÉäÅ£ÇåÂѰס¢½ÇĤ»ùÖÊÖ×Áö×éÖ¯Ö²ÈëÊõµÈ£©¿ÉÈËΪµØÓÕ·¢¶¯ÎïµÄ½ÇĤÐÂÉúѪ¹ÜÔöÉú £¬±¬·¢ÀàËÆÓÚÈËÀ༲²¡µÄÄ£×Ó¡£ÏÂÃæÖ÷ÒªÏÈÈݽÇĤÐÂÉúѪ¹ÜÑо¿×î³£ÓõÄÒªÁì——½ÇĤÄÒ´üÅжϷ¨¡£³£ÓõÄÓÕµ¼¼ÁÓÐÄÚ¶¾ËØ¡¢¼îÐÔ³ÉÏËάϸ°ûÉú³¤Òò×Ó(basic fibroblast growth factor, bFGF)¡¢Ñª¹ÜÄÚÆ¤Éú³¤Òò×Ó(vascular endothelial growth factor, VEGF)¡¢¶þÑõ»¯¹èµÈ £¬ÒÔ»ºÊÍÄÚ¶¾ËغÍbFGF»ºÊÍÒ©ÍèÓÕÉú½ÇĤÐÂÉúѪ¹Ü¶¯ÎïÄ£×ÓµÄÖÆ×÷ΪÀý £¬¾ÙÐмòÆÓÏÈÈÝ¡£

²¿·ÖÔìÄ£ÒªÁì

ʹÓö¯ÎʵÑ鶯Îï

¡¾ÔìÄ  £»úÖÆ¡¿£º

ÄÚ¶¾ËØÓÕÉúµÄCNV¼Ì·¢ÓÚÑ×Ö¢·´Ó¦ £¬²¢ÇÒÑ×Ö¢´Ì¼¤·´Ó¦ÓëÐÂÉúѪ¹ÜµÄÓÕÉú³ÊÕýÏà¹Ø £¬ÄÚ¶¾ËØÓÕÉúÐÂÉúѪ¹ÜÀú³Ì¿ÉÄÜÊܾÞÊÉϸ°ûÉøÍ¸µÄbFGFÒò×Óµ÷¿Ø £¬²¢ÇÒ±»¾ÞÊÉϸ°ûÉøÍ¸µÄÆäËûÒò×ÓÈçÖ×Áö»µËÀÒò×Ó-αºÍת»¯Éú³¤Òò×Ó-β·Å´ó¡£

bFGFÊǰüÀ¨146¸ö°±»ùËá¾ßÓÐÖØ´ó¹¦Ð§µÄµ¥Á´·ô £¬ÔÚһϵÁÐÌåÍâʵÑéÖÐ £¬±»Ö¤Êµ¾ßÓжÔѪ¹ÜÄÚÆ¤Ï¸°û·Ö½â¡¢ÔöÖ³¡¢Ç¨áãºÍÇ÷»¯×÷Óá£bFGFÓÕµ¼µÄ΢Ѫ¹ÜÄÚÆ¤Ï¸°û¿É±¬·¢´ó×ڵĵ-PA £¬ÔÚѪ¹ÜÌìÉúÔçÆÚÆðÖÐÐÄ×÷Óà £¬µ-PA½«ÏËάÂѰ×ÈÜøԭת»¯³É¾ßÓÐø»îÐÔµÄÏËάÂѰ×ÈÜø £¬ºóÕßÓֿɼ¤»î½ºÔ­Ã¸ £¬ÏûÈÚÐÂÉúѪ¹ÜÆðʼԵµÄ»ùĤ £¬²¢µ¼ÖÂÄÚÆ¤Ï¸°û½øÈëÈýάµÄ½ºÔ­»ùÖÊ £¬ÐγÉеÄëϸѪ¹ÜÑ¿¡£

¡¾ÔìÄ£ÒªÁì¡¿£º

»ºÊÍÄÚ¶¾ËؾۺÏÎïÒ©ÍèµÄÖÆ±¸£ºÒÒÏ©£­´×ËᣭÒÒϩ֬¾ÛºÏÎï(Elvax)Öé½ÓÄɸߴ¿µÄ¼ºÈ©Ï´åªÖÁ·Ö¹â¹â¶È´¿ £¬ÔÚÊÒÎÂϽ«¾ÛºÏÎïÈÜÓÚ¶þÂȼ×ÍéÖÁ10£¥(W/N)×îÖÕŨ¶È £¬½«Ò»¶¨±ÈÀýE.ColiÄÚ¶¾ËØÓë10£¥Elvax»ìÏý²¢Ç¿Á¦½Á°èÖÁÔȳÆÐüÒº¡£ÄÚ¶¾ËØ£­ElvaxÐüÒºÓÃÏû¶¾µÎ¹ÜµÎÈë8¿×²£Á§°å¾ÛºÏ £¬ÍêÈ«¾ÛºÏºó £¬ÖƳÉ1mm3¾Þϸ £¬£¨1.3±0.3)mg/Íè £¬×ÏÍâÏßÏû¶¾ºó-40¡æÔ̲ر¸Óá£

bFBF»ºÊÍÒ©ÍèµÄÖÆ±¸£ºbFBF»ºÊÍÒ©ÍèÓÉ»ºÊͼÁ¾Û¼×»ù±ûÏ©Ëᣭ2£­ôÇÒÒõ¥(Hydron)ºÍÒ»¶¨Á¿µÄÓÕµ¼¼ÁbFGF»ìÏý¶ø³É £¬ÔÚbFGF-Hydron»ºÊÍÒ©ÍèÖмÓÈëÒ»¶¨Á¿µÄÁòÌÇÂÁ(sucralfate) £¬ÖƳÉHydron°ü¹üµÄbFGF-sucralfate»ºÊÍÒ©Íè £¬¿ÉÓÐÓõØÎȹÌbFGFµÄÉúÎï»îÐÔ £¬¼õ»ºbFGFµÄÊÍ·Å¡£

½ÇĤÄÒ´üÖÆ×÷£ºËùÓÐÊÖÊõ°ì·¨¾ùÔÚÎÞ¾úÌõ¼þϾÙÐÐ £¬3£¥Îì°Í±ÈÍ×ÄÆÍöúÔµ¾²Âö×¢ÉäÈ«ÉíÂé×í(25mg/kg), 1£¥µØ¿¨Òò¾Ö²¿µãÑÛÂé×í £¬ÔÚ½ÇĤÖÐÑë×÷1.5mm¡¢1/2½ÇĤºñ¶ÈÇÐ¿Ú £¬Ïò6µãλDZÐÐÊèÉ¢1/2ºñ½ÇĤÄÒ´ü £¬ÖÁ¾à½ÇĤԵ2.0mm´¦ £¬½ÓÄɲ£Á§Ì×¹ÜÖ²ÈëÖÆ±¸ºÃµÄ»ºÊÍÒ©Íè £¬½«ÄÒ´üÇпÚÖØÐ¸´Î» £¬ÒÔ±ãÓúºÏ¡£

¡¾Ä£×ÓÌØµã¡¿£º

CNVÓë¾Ö²¿ÄÚ¶¾ËسʼÁЧÒÀÀµ¹ØÏµ¡£ÓÃŨ¶ÈΪ15£¥ÄÚ¶¾ËؾۺÏÎïÄÜ»ñµÃÏÔÖøµÄ½ÇĤÐÂÉúѪ¹ÜÉú³¤ £¬½ö°éÓÐÉÔ΢µÄ½ÇĤˮÖ× £¬ÄÜÓÕÉúÏàÒ˵ÄCNV¶¯ÎïÄ£×Ó £¬ÄÚ¶¾ËØÅ¨¶È¹ý¸ßÔòÒýÆðÏÔÖøµÄ½ÇĤÑ×Ö¢ £¬»ùÖÊ»ì×Dz¢ÇÒÐÂÉúѪ¹ÜÉú³¤Ò×ÈÚºÏ £¬Ó°ÏìÐÂÉúѪ¹ÜÕÉÁ¿ºÍÅÌËãµÄ׼ȷÐÔ £¬Å¨¶ÈÌ«µÍÔòÓÕµ¼Á¦¶È¹ýС £¬²»ÊʺÏÄ£×ÓµÄÒªÇó¡£

¡¾Ä£×ÓÆÀ¹ÀºÍÓ¦Óá¿£º

»ºÊÍÄÚ¶¾ËؾۺÏÎïÒ©ÍèÓÕÉúCNVÄ£×ÓµÄÓŵãÊÇ£ºÐÂÉúѪ¹Ü¶¨Ïò³ÉÊøÉú³¤ £¬ ÖØ¸´ÎÈ¹Ì £¬²â¶¨ºÍ¶¨Á¿ÆÊÎöµÄ׼ȷÐÔÏÔ×ÅÌá¸ß £¬²¢ÇҿɽÓÄÉÅÌËã»úͼÏñÆÊÎöϵͳ¾ÙÐÐÖðÈÕÒ»Á¬¶¯Ì¬¶¨Á¿²â¶¨ £¬Àû±ãÓë±ÈÕÕ×é½ÏÁ¿¡£

bFGF»ºÊÍÒ©ÍèÓÕÉúµÄCNV¶¯ÎïÄ£×ÓµÄÓŵãÔÚÓÚ£ºbFGF×÷ΪÐÂÉúѪ¹ÜµÄÖ±½Ó´Ì¼¤Òò×Ó £¬¿Éɨ³ýÑ×Ö¢µÈ¼ä½ÓÐÂÉúѪ¹Ü´Ì¼¤ÒòËØ £¬Õâ¹ØÓÚÌØ¶¨µÄÐÂÉúѪ¹ÜÒÖÖÆ¼ÁµÄÁÆÐ§ÆÀ¼ÛÓÐÖ÷ÒªÒâÒå  £»±ãÓÚ¶¨Á¿ÆÊÎö  £»ÎȹÌÐÔºÍÖØ¸´ÐÔ¾ã¼ÑÇÒ¾­¼ÃÊÊÓá£

 

²Î¿¼ÎÄÏ×£º

1.ÇñÅàèª. ½ÇĤÐÂÉúѪ¹ÜµÄ¶¯ÎïÄ£×Ó£®ÍâÑóҽѧ£ºÑÛ¿ÆÑ§·Ö²á £¬2000, 24 (6):360-363

2.ºú¶«¶« £¬Íõ¼ÎÈÝ £¬ÑîÔÚ¸»£®¼¤¹âÑÛËðÉ˶¯ÎïУÐÍÑо¿Ï£Íû£®¾üÊÂҽѧ¿ÆÑ§ÔºÔº¿¯ £¬2010,5:489-491

3.Äô°®ÇÛ £¬Ï¯Ãç £¬Ï¯ÐË»ª £¬µÈ´¿´â°ÌÕ¶¾ÐÔ½ÇĤÑ×¢òÊóÄ£×ӵĽ¨Éè¼°ÅжϹú¼ÊÑÛ¿ÆÔÓÖ¾ £¬2012,12(11): 2059-2061

4.ÐìÑÒ±äÓ¦ÐÔ½áĤÑ×¶¯ÎïÄ£×ÓÑÛ¿ÆÑо¿ £¬2001, 19(2):181-183

5.κÈ𻪠£¬ºÂÓÀÄÈ £¬ÕÔÉÙÕ꣮×ÔÉíÃâÒßÏà¹ØÐÔ¸ÉÑÛ¶¯ÎïÄ£×ÓµÄÑо¿Ï£Íû£®ÑÛ¿ÆÐÂÏ£Íû £¬2012, 32 (7):690-693

6.Calonge MC, Pastor JC, Herreras JM, el al. Pharmacologic modulation of vascular permeability in ocular allergy in the rat. Invest Ophthalmol Vis Sci, 1990, 31 (1): 176-180

7.Marquart ME.Animal models of bacterial keratitis.J Biomed Biotechnol,2011,2011:680642

8.Pavan-Langston D. Herpes simplex virus ocular infections:current concepts of acute, latent and reactivated disease. Trans Am Ophthalmol Soc, 1990,88:727-796

 

sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Ä£×ÓĿ¼
Ä¿½ñλÖãºÊ×Ò³ > ÈËÀ༲²¡¶¯ÎïÄ£×ÓĿ¼ > ÑۿƼ²²¡Ä£×Ó > ½ÇĤÐÂÉúѪ¹Ü¶¯ÎïÄ£×Ó
½ÇĤÐÂÉúѪ¹Ü¶¯ÎïÄ£×Ó

ǰÑÔ

½ÇĤÐÂÉúѪ¹Ü(ehoroidal neovascularization,CNV)³£µ¼Ö½ÇĤ͸Ã÷¶È½µµÍ £¬ÊÇÖÂäµÄÒ»¸öÖ÷ÒªÔµ¹ÊÔ­ÓÉ £¬Ò²ÊǽÇÄ¤ÒÆÖ²Êõºó±¬·¢ÇãÔþ·´Ó¦µÄ¸ßΣÒòËØ¡£ÁÙ´²ÉÏCNVÖÎÁÆÈÔÊÇ×ÊÖµÄÎÊÌâÖ®Ò»¡£CNV¶¯ÎïÄ£×ÓÊôÓÚÓÕ·¢ÐÔ¼²²¡¶¯ÎïÄ£×Ó £¬Í¨¹ýÎïÀíÒªÁ죨ÈÈÉÕÀÓÊõºÍ½ÇĤ·ìÏß·¨µÈ£©¡¢»¯Ñ§ÒªÁ죨¼îÐÔ»¯Ñ§Ò©ÎïÉÕÉ˵ȣ©¡¢ÉúÎïÒªÁ죨½ÇĤÄÒ´üÅжϷ¨£©ºÍÊÖÊõÒªÁ죨ÒìÖÖ½ÇÄ¤ÒÆÖ²¡¢½ÇĤ»ùÖÊÄÚ×¢ÉäÅ£ÇåÂѰס¢½ÇĤ»ùÖÊÖ×Áö×éÖ¯Ö²ÈëÊõµÈ£©¿ÉÈËΪµØÓÕ·¢¶¯ÎïµÄ½ÇĤÐÂÉúѪ¹ÜÔöÉú £¬±¬·¢ÀàËÆÓÚÈËÀ༲²¡µÄÄ£×Ó¡£ÏÂÃæÖ÷ÒªÏÈÈݽÇĤÐÂÉúѪ¹ÜÑо¿×î³£ÓõÄÒªÁì——½ÇĤÄÒ´üÅжϷ¨¡£³£ÓõÄÓÕµ¼¼ÁÓÐÄÚ¶¾ËØ¡¢¼îÐÔ³ÉÏËάϸ°ûÉú³¤Òò×Ó(basic fibroblast growth factor, bFGF)¡¢Ñª¹ÜÄÚÆ¤Éú³¤Òò×Ó(vascular endothelial growth factor, VEGF)¡¢¶þÑõ»¯¹èµÈ £¬ÒÔ»ºÊÍÄÚ¶¾ËغÍbFGF»ºÊÍÒ©ÍèÓÕÉú½ÇĤÐÂÉúѪ¹Ü¶¯ÎïÄ£×ÓµÄÖÆ×÷ΪÀý £¬¾ÙÐмòÆÓÏÈÈÝ¡£

²¿·ÖÔìÄ£ÒªÁì

ʹÓö¯ÎʵÑ鶯Îï

¡¾ÔìÄ  £»úÖÆ¡¿£º

ÄÚ¶¾ËØÓÕÉúµÄCNV¼Ì·¢ÓÚÑ×Ö¢·´Ó¦ £¬²¢ÇÒÑ×Ö¢´Ì¼¤·´Ó¦ÓëÐÂÉúѪ¹ÜµÄÓÕÉú³ÊÕýÏà¹Ø £¬ÄÚ¶¾ËØÓÕÉúÐÂÉúѪ¹ÜÀú³Ì¿ÉÄÜÊܾÞÊÉϸ°ûÉøÍ¸µÄbFGFÒò×Óµ÷¿Ø £¬²¢ÇÒ±»¾ÞÊÉϸ°ûÉøÍ¸µÄÆäËûÒò×ÓÈçÖ×Áö»µËÀÒò×Ó-αºÍת»¯Éú³¤Òò×Ó-β·Å´ó¡£

bFGFÊǰüÀ¨146¸ö°±»ùËá¾ßÓÐÖØ´ó¹¦Ð§µÄµ¥Á´·ô £¬ÔÚһϵÁÐÌåÍâʵÑéÖÐ £¬±»Ö¤Êµ¾ßÓжÔѪ¹ÜÄÚÆ¤Ï¸°û·Ö½â¡¢ÔöÖ³¡¢Ç¨áãºÍÇ÷»¯×÷Óá£bFGFÓÕµ¼µÄ΢Ѫ¹ÜÄÚÆ¤Ï¸°û¿É±¬·¢´ó×ڵĵ-PA £¬ÔÚѪ¹ÜÌìÉúÔçÆÚÆðÖÐÐÄ×÷Óà £¬µ-PA½«ÏËάÂѰ×ÈÜøԭת»¯³É¾ßÓÐø»îÐÔµÄÏËάÂѰ×ÈÜø £¬ºóÕßÓֿɼ¤»î½ºÔ­Ã¸ £¬ÏûÈÚÐÂÉúѪ¹ÜÆðʼԵµÄ»ùĤ £¬²¢µ¼ÖÂÄÚÆ¤Ï¸°û½øÈëÈýάµÄ½ºÔ­»ùÖÊ £¬ÐγÉеÄëϸѪ¹ÜÑ¿¡£

¡¾ÔìÄ£ÒªÁì¡¿£º

»ºÊÍÄÚ¶¾ËؾۺÏÎïÒ©ÍèµÄÖÆ±¸£ºÒÒÏ©£­´×ËᣭÒÒϩ֬¾ÛºÏÎï(Elvax)Öé½ÓÄɸߴ¿µÄ¼ºÈ©Ï´åªÖÁ·Ö¹â¹â¶È´¿ £¬ÔÚÊÒÎÂϽ«¾ÛºÏÎïÈÜÓÚ¶þÂȼ×ÍéÖÁ10£¥(W/N)×îÖÕŨ¶È £¬½«Ò»¶¨±ÈÀýE.ColiÄÚ¶¾ËØÓë10£¥Elvax»ìÏý²¢Ç¿Á¦½Á°èÖÁÔȳÆÐüÒº¡£ÄÚ¶¾ËØ£­ElvaxÐüÒºÓÃÏû¶¾µÎ¹ÜµÎÈë8¿×²£Á§°å¾ÛºÏ £¬ÍêÈ«¾ÛºÏºó £¬ÖƳÉ1mm3¾Þϸ £¬£¨1.3±0.3)mg/Íè £¬×ÏÍâÏßÏû¶¾ºó-40¡æÔ̲ر¸Óá£

bFBF»ºÊÍÒ©ÍèµÄÖÆ±¸£ºbFBF»ºÊÍÒ©ÍèÓÉ»ºÊͼÁ¾Û¼×»ù±ûÏ©Ëᣭ2£­ôÇÒÒõ¥(Hydron)ºÍÒ»¶¨Á¿µÄÓÕµ¼¼ÁbFGF»ìÏý¶ø³É £¬ÔÚbFGF-Hydron»ºÊÍÒ©ÍèÖмÓÈëÒ»¶¨Á¿µÄÁòÌÇÂÁ(sucralfate) £¬ÖƳÉHydron°ü¹üµÄbFGF-sucralfate»ºÊÍÒ©Íè £¬¿ÉÓÐÓõØÎȹÌbFGFµÄÉúÎï»îÐÔ £¬¼õ»ºbFGFµÄÊÍ·Å¡£

½ÇĤÄÒ´üÖÆ×÷£ºËùÓÐÊÖÊõ°ì·¨¾ùÔÚÎÞ¾úÌõ¼þϾÙÐÐ £¬3£¥Îì°Í±ÈÍ×ÄÆÍöúÔµ¾²Âö×¢ÉäÈ«ÉíÂé×í(25mg/kg), 1£¥µØ¿¨Òò¾Ö²¿µãÑÛÂé×í £¬ÔÚ½ÇĤÖÐÑë×÷1.5mm¡¢1/2½ÇĤºñ¶ÈÇÐ¿Ú £¬Ïò6µãλDZÐÐÊèÉ¢1/2ºñ½ÇĤÄÒ´ü £¬ÖÁ¾à½ÇĤԵ2.0mm´¦ £¬½ÓÄɲ£Á§Ì×¹ÜÖ²ÈëÖÆ±¸ºÃµÄ»ºÊÍÒ©Íè £¬½«ÄÒ´üÇпÚÖØÐ¸´Î» £¬ÒÔ±ãÓúºÏ¡£

¡¾Ä£×ÓÌØµã¡¿£º

CNVÓë¾Ö²¿ÄÚ¶¾ËسʼÁЧÒÀÀµ¹ØÏµ¡£ÓÃŨ¶ÈΪ15£¥ÄÚ¶¾ËؾۺÏÎïÄÜ»ñµÃÏÔÖøµÄ½ÇĤÐÂÉúѪ¹ÜÉú³¤ £¬½ö°éÓÐÉÔ΢µÄ½ÇĤˮÖ× £¬ÄÜÓÕÉúÏàÒ˵ÄCNV¶¯ÎïÄ£×Ó £¬ÄÚ¶¾ËØÅ¨¶È¹ý¸ßÔòÒýÆðÏÔÖøµÄ½ÇĤÑ×Ö¢ £¬»ùÖÊ»ì×Dz¢ÇÒÐÂÉúѪ¹ÜÉú³¤Ò×ÈÚºÏ £¬Ó°ÏìÐÂÉúѪ¹ÜÕÉÁ¿ºÍÅÌËãµÄ׼ȷÐÔ £¬Å¨¶ÈÌ«µÍÔòÓÕµ¼Á¦¶È¹ýС £¬²»ÊʺÏÄ£×ÓµÄÒªÇó¡£

¡¾Ä£×ÓÆÀ¹ÀºÍÓ¦Óá¿£º

»ºÊÍÄÚ¶¾ËؾۺÏÎïÒ©ÍèÓÕÉúCNVÄ£×ÓµÄÓŵãÊÇ£ºÐÂÉúѪ¹Ü¶¨Ïò³ÉÊøÉú³¤ £¬ ÖØ¸´ÎÈ¹Ì £¬²â¶¨ºÍ¶¨Á¿ÆÊÎöµÄ׼ȷÐÔÏÔ×ÅÌá¸ß £¬²¢ÇҿɽÓÄÉÅÌËã»úͼÏñÆÊÎöϵͳ¾ÙÐÐÖðÈÕÒ»Á¬¶¯Ì¬¶¨Á¿²â¶¨ £¬Àû±ãÓë±ÈÕÕ×é½ÏÁ¿¡£

bFGF»ºÊÍÒ©ÍèÓÕÉúµÄCNV¶¯ÎïÄ£×ÓµÄÓŵãÔÚÓÚ£ºbFGF×÷ΪÐÂÉúѪ¹ÜµÄÖ±½Ó´Ì¼¤Òò×Ó £¬¿Éɨ³ýÑ×Ö¢µÈ¼ä½ÓÐÂÉúѪ¹Ü´Ì¼¤ÒòËØ £¬Õâ¹ØÓÚÌØ¶¨µÄÐÂÉúѪ¹ÜÒÖÖÆ¼ÁµÄÁÆÐ§ÆÀ¼ÛÓÐÖ÷ÒªÒâÒå  £»±ãÓÚ¶¨Á¿ÆÊÎö  £»ÎȹÌÐÔºÍÖØ¸´ÐÔ¾ã¼ÑÇÒ¾­¼ÃÊÊÓá£

 

²Î¿¼ÎÄÏ×£º

1.ÇñÅàèª. ½ÇĤÐÂÉúѪ¹ÜµÄ¶¯ÎïÄ£×Ó£®ÍâÑóҽѧ£ºÑÛ¿ÆÑ§·Ö²á £¬2000, 24 (6):360-363

2.ºú¶«¶« £¬Íõ¼ÎÈÝ £¬ÑîÔÚ¸»£®¼¤¹âÑÛËðÉ˶¯ÎïУÐÍÑо¿Ï£Íû£®¾üÊÂҽѧ¿ÆÑ§ÔºÔº¿¯ £¬2010,5:489-491

3.Äô°®ÇÛ £¬Ï¯Ãç £¬Ï¯ÐË»ª £¬µÈ´¿´â°ÌÕ¶¾ÐÔ½ÇĤÑ×¢òÊóÄ£×ӵĽ¨Éè¼°ÅжϹú¼ÊÑÛ¿ÆÔÓÖ¾ £¬2012,12(11): 2059-2061

4.ÐìÑÒ±äÓ¦ÐÔ½áĤÑ×¶¯ÎïÄ£×ÓÑÛ¿ÆÑо¿ £¬2001, 19(2):181-183

5.κÈ𻪠£¬ºÂÓÀÄÈ £¬ÕÔÉÙÕ꣮×ÔÉíÃâÒßÏà¹ØÐÔ¸ÉÑÛ¶¯ÎïÄ£×ÓµÄÑо¿Ï£Íû£®ÑÛ¿ÆÐÂÏ£Íû £¬2012, 32 (7):690-693

6.Calonge MC, Pastor JC, Herreras JM, el al. Pharmacologic modulation of vascular permeability in ocular allergy in the rat. Invest Ophthalmol Vis Sci, 1990, 31 (1): 176-180

7.Marquart ME.Animal models of bacterial keratitis.J Biomed Biotechnol,2011,2011:680642

8.Pavan-Langston D. Herpes simplex virus ocular infections:current concepts of acute, latent and reactivated disease. Trans Am Ophthalmol Soc, 1990,88:727-796

 

¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿